Drug Profile
Research programme: fusion protein cancer therapeutics - Aida Pharmaceuticals
Alternative Names: Vasostatin-Apo2LLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aida Pharmaceuticals; Shanghai Qiaer Bio-Technology
- Developer Shanghai Qiaer Bio-Technology
- Class Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 15 Mar 2007 Preclinical trials in Solid tumours in China (unspecified route)